➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
McKesson
Boehringer Ingelheim
Merck
AstraZeneca

Last Updated: July 31, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SYM004


Email this page to a colleague

« Back to Dashboard

Clinical Trials for Sym004

Trial ID Title Status Sponsor Phase Summary
NCT01117428 ↗ Sym004 in Patients With Advanced Solid Tumors Completed Symphogen A/S Phase 1/Phase 2 This trial is designed as a multi-centre, open label, dose-escalation, phase I trial and consists of five parts.
NCT01417936 ↗ Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy Completed Symphogen A/S Phase 2 The trial is designed as a multi-center, open label Phase 2 trial that investigates the efficacy and safety of Sym004 in subjects with squamous cell cancer of the head and neck (SCCHN). Subjects included must have responded to previous anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody-based therapy and subsequently become resistant to that therapy. It is believed that Sym004 has the potential to induce tumor responses and provide a superior treatment option to subjects with advanced SCCHN. Symphogen was the sponsor for planning/conducting and reporting results for this trial.
NCT01955473 ↗ Japanese Phase 1 Trial of Sym004 in Solid Tumors Completed Merck KGaA Phase 1 This is a Phase 1, open-label, dose-escalation trial to assess the safety and tolerability of Sym004, administered weekly or biweekly as monotherapy in Japanese subjects with advanced solid tumors.
NCT02083653 ↗ Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer Active, not recruiting Symphogen A/S Phase 2 This is a Phase 2, open-label, 3-arm trial of two Sym004 doses (Arms A and B) and a control group (Arm C) in subjects with metastatic colorectal cancer (mCRC) and acquired resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs).
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for Sym004

Condition Name

Condition Name for
Intervention Trials
Metastatic Colorectal Cancer 6
Colorectal Cancer Metastatic 2
Carcinoma 2
Malignant Glioma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for
Intervention Trials
Colorectal Neoplasms 6
Carcinoma 3
Colonic Neoplasms 2
Carcinoma, Non-Small-Cell Lung 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Sym004

Trials by Country

Trials by Country for
Location Trials
United States 24
Germany 5
Spain 5
Belgium 4
Italy 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for
Location Trials
California 4
North Carolina 3
Texas 3
Georgia 2
District of Columbia 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Sym004

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 3 1
Phase 2 5
Phase 1/Phase 2 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Recruiting 4
Completed 3
Not yet recruiting 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Sym004

Sponsor Name

Sponsor Name for
Sponsor Trials
Symphogen A/S 9
Merck KGaA 1
Annick Desjardins 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 11
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Moodys
McKesson
Merck
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.